December 26, 2019
Ono Pharmaceutical and Bristol-Myers Squibb said on December 25 that they have filed their immuno-oncology combination therapy pairing Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in Japan. The combo therapy was...read more